HealthInsu™ — The Model

A prevention subscription, paired with an insurance benefit.

Consumers subscribe to disease-prevention products on a regular basis. If a covered disease occurs, they receive an insurance benefit. From the consumer's point of view, they manage their health while gaining financial protection if illness happens.

Why this model is powerful

Three groups benefit at once. That is what makes it durable.

Consumers

Health + protection

They subscribe because they want to take care of their health — and because they value the insurance protection that comes with it.

Manufacturers

Recurring revenue

Subscription-based consumption creates durable recurring revenue, not one-off shelf sales — and category loyalty compounds.

Insurers

New short-term group line

A new short-term group insurance line, priced on actual cohort data — small per-cycle premiums, predictable volume, and tighter loss ratios than broad-population underwriting.

If a local partner can connect insurance companies with health-product manufacturers, HealthInsu™ becomes a patented global business model that can be localized in many countries. Securing the license means gaining a unique position in the local preventive-healthcare market.

How the insurer earns

A new short-term group insurance line, priced on data — not assumption.

The insurer side of HealthInsu™ is not a long-tail life or critical-illness liability. It is structured as a recurring short-term group policy, sized to the subscription cohort and priced on the cohort's own prevention data.

Policy structure

Group short-term contracts

Benefits are typically issued as group short-term insurance contracts. Each subscription cycle generates one small policy premium. Volume scales with the subscription base — predictable, recurring, and cleanly separated from long-tail life or critical-illness liabilities on the insurer's book.

Loss-ratio advantage

Priced on actual prevention data

Subscribers carry a pre-enrollment baseline (intake examination, biomarkers) and an ongoing usage record. Insurers underwrite against actual cohort data rather than broad-population tables — reducing adverse selection and tightening the loss ratio over the first 12 months of operation.

Acquisition

Zero direct acquisition cost

The insurer reaches the insured pool through the manufacturer's existing subscription channel — no separate marketing spend, no broker commission stack. The benefit ships as part of the product, not as a standalone policy to sell.

Cross-sell pipeline

Warm leads for traditional lines

Subscribers who complete a year of the structured prevention routine — or who experience a benefit payout — become qualified, opt-in candidates for the insurer's traditional health, cancer, or critical-illness products. The HealthInsu™ cohort becomes a top-of-funnel for the rest of the book.

Actual policy structure (term length, cover scope, premium split, reinsurance treatment) is defined per country and per partner insurer under separate agreement. HealthInsu™ provides the framework; local regulation determines the contract form.

How it works in practice

A six-step structure, run end-to-end by your country team.

Step 01

Select & validate

Choose a disease-specific prevention product and validate it against your local market and regulation.

Step 02

Connect clinical

Wire the product to physicians, examinations, and check-up systems.

Step 03

Subscribe

Consumers subscribe — monthly or through a structured trial program.

Step 04

Confirm results

Results are confirmed through tests, biomarkers, or follow-up examinations.

Step 05

Link to insurance

Link the product to an insurance benefit to build trust and reduce buyer hesitation.

Step 06

Compound trust

A validated product compounds advantage over legacy brand-driven products as the loop runs.

The patent layer

Protected at the structure level, not just the product.

Business-model patents

Prevention + insurance, structured

The subscription-to-benefit linkage between preventive products and insurance is protected as a business-model patent — not just a single product claim.

System patents

Validation and verification systems

The validation flow (clinic, examination, biomarker, follow-up) is protected as a system patent, layered on top of the business-model claim.

Patent protection is built in multiple layers — typically two to four — so the model holds across jurisdictions and product categories. Country-level licensing terms are defined under separate agreement.

Not a guarantee — a structured risk-sharing program

The framing matters.

HealthInsu™ is not a "we guarantee disease prevention" license. It is a B2B framework that reduces the verification gap consumers feel in the prevention category — through 1-year usage data, conditional compensation structures, and operating standards co-defined per licensee.

For licensees

Lower buyer hesitation, higher retention

The risk-sharing layer lowers purchase friction for higher-ticket and subscription products, and improves 12-month retention by tying continued use to the benefit structure.

For consumers

Verified usage, not promises

Consumers see a transparent 1-year structure with defined check-in points — not marketing claims about cure or guaranteed prevention.

Pilot-first, then scale

We typically start with one product and one customer cohort, structured as a 100-person pilot (then 300, then 1,000) over a 12-month observation window. A pilot is designed to measure purchase conversion, retention, satisfaction, repurchase rate, and compensation claim rate — not to confirm medical efficacy. Pilot results inform the full license terms.

See license terms →